fashion -WSS

fashion

author：hotspot 2025-09-28 09:21:24 - browse：869

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Gene editing the human germline: What are the risks?

WSS

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Physicians and social media: If you see something, say something?

Virtual Event: March of the Biosimilars

Medical device trials still don't enroll enough women, study finds

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Report captures long Covid’s disabling effects and policy challenges

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Heart attack and stroke risk calculators need revising

New report analyzes digital physical therapy solutions' effectiveness

Guidelines to prevent youth baseball injuries need more muscle

U.K. researchers warn about biases in medical devices, algorithms

How one medical school became remarkably diverse

Colonoscopy prep: Liquid

Medical leaders decry Supreme Court decision on affirmative action

Gene editing the human germline: What are the risks?

Novavax promises a turnaround & Lilly roils the obesity market

Pharma companies must ensure equitable access to obesity drugs

leisure time

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Colonoscopy prep: Liquid

AstraZeneca to buy developer of next

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Pharma companies must ensure equitable access to obesity drugs

Baby aspirin cuts fat buildup in liver disease patients, in small study

Wikipedia

hotspot

knowledge

knowledge